Consensus Lundbeck Wiener Boerse

Stocks

LUNA

DK0061804697

Pharmaceuticals

End-of-day quote Wiener Boerse 20/08/2026			5-day change	1st Jan Change
5.360 ^EUR	-4.46%		+12.13%	+10.97%

08-20	Cancer vaccines finally garner the spotlight
08-20	UBS raises Lundbeck price target to 45 Danish kroner (44), reiterates neutral	FW

Evolution of the Average Target: Lundbeck

Evolution of the Target Price: Lundbeck

Changes in Analyst Recommendations: Lundbeck

7d2311a20.qOhFL9O4MIHebbQFf56Ru18lGxglVVIxKTFgqY9qzs8.-4MkHrLhcvCkFPlaHa_c1zpfI3pVMWUAZkBS294IiaP33gAaiedc778fjA~774bab925a32835febdad7b90973f7f5

Analysts' recommendations: Lundbeck

08-20	Cancer vaccines finally garner the spotlight
08-20	UBS raises Lundbeck price target to 45 Danish kroner (44), reiterates neutral	FW
08-19	H Lundbeck: Q2 beat, but pipeline execution remains non-negotiable
08-17	Lundbeck expected to report DKK 1,945m in adjusted EBITDA, consensus	FW
07-17	Barclays raises price target for Lundbeck to 48 Danish kroner (45), reiterates equal weight - BN	FW
07-14	Where would AI lead Pharma in the long run?
07-13	Danske Bank raises Lundbeck price target to 57 Danish kroner (55), reiterates buy - BN	FW
06-18	Nordea raises target price for Lundbeck to DKK60 (57), reiterates buy rating	FW
05-13	H Lundbeck: Strong Q1, but long-term growth uncertainty hovers over valuation
05-13	Nordea raises Lundbeck price target to DKK 57 (55), reiterates Buy	FW
05-13	DNB Carnegie raises Lundbeck price target to DKK 54 (53), reiterates Buy	FW
04-28	SEB raises Lundbeck price target to DKK 46 (43), reiterates Hold	FW
04-27	UBS raises Lundbeck price target to DKK 44 (42), reiterates Neutral	FW
03-23	H. Lundbeck Price Target Down as AlphaValue/Baader Europe Expects Patent Expirations to Weigh on Growth	MT
03-20	H Lundbeck: Markets need more proof of growth promise
03-05	Nordea Resumes Coverage of Lundbeck With Buy Rating – Too Cheap to Ignore	FW
03-05	Nordea Resumes Coverage of Lundbeck with Buy Rating and Price Target of 55 Danish Kroner	FW
03-02	Jefferies Upgrades Lundbeck to Hold (Underperform), Sets Price Target at 39 Danish Kroner	FW
02-17	Deutsche Bank Lowers Price Target for Lundbeck to 40 Danish Kroner (44), Maintains Hold Recommendation	FW
02-16	DNB Carnegie Raises Price Target for Lundbeck to 53 Danish Kroner (51), Reiterates Buy	FW
02-12	Barclays Lowers Price Target for Lundbeck to 45 Danish Kroner (from 50), Maintains Equal Weight - BN	FW
02-06	H Lundbeck: Weak 2026 outlook a turn-off for investors
02-05	Danske Bank Lowers Price Target for Lundbeck to 48 Danish Kroner (52), Reiterates Buy - BN	FW
02-05	UBS Lowers Price Target for Lundbeck to 42 Danish Kroner (46), Reiterates Neutral Rating	FW
02-05	SEB Lowers Price Target for Lundbeck to 43 Danish Kroner (from 50), Maintains Hold Recommendation	FW

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
LUNDBECK	-	-	-	-
MCKESSON CORPORATION				+15.61%
CARDINAL HEALTH, INC.				+15.37%
SIGMA HEALTHCARE LIMITED				+13.84%
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD				+26.13%
HUADONG MEDICINE CO., LTD				+62.2%
SINOPHARM GROUP CO. LTD.				+36.11%
H. LUNDBECK A/S				+13.34%
GALENICA AG	-			+8.42%
MEDIPAL HOLDINGS CORPORATION				+2.77%
Average				+21.53%
Weighted average by Cap.				+17.53%